Carregant...
The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is currently approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC) in combination with chemotherapy in first- and second-line and as monotherapy in chemorefractor...
Guardat en:
| Publicat a: | Cancer Manag Res |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6607986/ https://ncbi.nlm.nih.gov/pubmed/31388315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S186042 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|